Retatrutide
GLP-1 + GIP + Glucagon triple receptor agonist (Eli Lilly LY3437943)
A first-in-class triple agonist hitting GLP-1, GIP, and glucagon receptors. The glucagon arm forces direct hepatic fat oxidation — making Retatrutide the most powerful weight-loss peptide currently in clinical trials. Phase III TRIUMPH program is ongoing; not yet FDA-approved. Practitioner usage requires careful titration due to amplified GI side effects.
Quick reference
How Retatrutide works
Retatrutide is the first triple agonist targeting GLP-1, GIP, and glucagon receptors. The GLP-1 arm provides standard appetite suppression and improved insulin sensitivity. The GIP arm partitions nutrients toward muscle (same mechanism as Tirzepatide). The glucagon arm is the breakthrough — it forces direct hepatic fat oxidation independent of caloric deficit.
Mechanistically, the glucagon component is what enables Retatrutide to drive weight loss faster than Tirzepatide at equivalent doses. Phase II data (Jastreboff 2023) showed -24.2% bodyweight at 12 mg over 48 weeks. For comparison, Tirzepatide's SURMOUNT-1 reached -22.5% over 72 weeks at 15 mg. The TRIUMPH-1 trial extends this to phase III with longer follow-up.
The glucagon arm also drives direct liver fat reduction — practitioner reports describe meaningful improvement in NAFLD / hepatic steatosis markers within 12-16 weeks at therapeutic doses. This is biologically distinct from GLP-1-only weight loss (which improves liver fat indirectly via overall fat loss).
Critical practical note: Retatrutide is not yet FDA-approved. Practitioner availability is via research-chemical channels with the standard caveats — purity verification (HPLC + mass spec) is non-negotiable, and ongoing trial safety data may surface contraindications not yet known.
Safety + side-effect profile
GI side effects are amplified vs Tirzepatide due to the additional glucagon arm. Slow titration matters even more here.
Documented serious risks (trial data): pancreatitis (rare, similar to Tirzepatide), gallbladder issues, mild transient elevations in liver enzymes (typically resolves; reflects increased hepatic fat oxidation). MTC theoretical FDA caution applies. Contraindications: type 1 diabetes, severe gastroparesis, active gallbladder disease, MEN-2 / family history of MTC, pregnancy, lactation, active hepatitis.
Critical interactions: never stack with Semaglutide, Tirzepatide, or Liraglutide — all hit GLP-1 receptors, no added efficacy, compounded GI burden. Caution with sulfonylureas and insulin (hypoglycemia risk despite glucagon arm — net effect is still hypoglycemic at therapeutic dose). Birth control absorption reduced during slow gastric emptying.
Lean mass + heart rate: Retatrutide can transiently elevate resting heart rate 5-10 bpm during active titration (glucagon arm). Most users normalize within 8-12 weeks. Lean mass preservation requires aggressive resistance training + 1.6-2.2 g protein per kg per day.
- • Nausea (severe in titration; 50-60% in first 4 weeks)
- • Constipation more common than diarrhea
- • Transient mild liver enzyme elevation (reflects hepatic fat oxidation)
- • Resting heart rate +5-10 bpm during titration
- • Reflux / GERD (especially with large meals)
- • Loss of food noise (intended effect)
Frequently asked
What is Retatrutide?
Retatrutide (Eli Lilly LY3437943) is a first-in-class triple receptor agonist hitting GLP-1, GIP, and glucagon receptors. Phase III TRIUMPH program is ongoing. The glucagon arm forces direct hepatic fat oxidation, making it the most powerful weight-loss peptide currently in clinical development.
Retatrutide vs Tirzepatide — which is more effective?
Retatrutide phase II showed -24.2% bodyweight at 12 mg over 48 weeks (Jastreboff 2023). Tirzepatide SURMOUNT-1 showed -22.5% at 15 mg over 72 weeks. Retatrutide is faster-acting and includes direct liver fat reduction via the glucagon arm. Side-effect profile is more aggressive — slower titration is essential. Tirzepatide is FDA-approved; Retatrutide is not yet.
What is the typical Retatrutide titration?
TRIUMPH-1 phase III protocol: 2 mg × 4 weeks → 4 mg × 4 weeks → 6 mg × 4 weeks → 8 mg × 4 weeks → 10 mg × 4 weeks → 12 mg maintenance. Some practitioners titrate slower (every 6 weeks) to manage GI side effects. Target dose is goal-dependent — 8 mg is often sufficient for moderate weight loss; 12 mg is for aggressive protocols.
Should I switch from Tirzepatide to Retatrutide?
Only if Tirzepatide has plateaued and weight loss is still a priority. Practitioner approach: stop Tirzepatide → wait 2 weeks (5-day half-life clearance) → start Retatrutide at 2 mg with full re-titration. Don't stack the two. Note: Retatrutide is not FDA-approved, so insurance coverage and quality assurance differ.
Does Retatrutide help with NAFLD / fatty liver?
Yes — this is one of the most-cited differential benefits. The glucagon arm drives direct hepatic fat oxidation independent of overall weight loss. Practitioner reports describe meaningful improvement in NAFLD markers within 12-16 weeks. Trial data is emerging (TRIUMPH-NASH).
What are the long-term safety concerns?
Phase II safety data (52 weeks) is reassuring at therapeutic doses. Phase III TRIUMPH program will provide long-term cardiovascular outcomes data. Documented risks: pancreatitis (rare), gallbladder issues, transient liver enzyme elevation, mild HR elevation during titration. MTC theoretical FDA caution applies. Long-term safety profile is still maturing.
Is Retatrutide research-chemical only right now?
Yes, until FDA approval (expected 2026-2027 based on TRIUMPH timeline). Practitioner availability is via research-chemical channels. This means: purity verification (HPLC + mass spec) is non-negotiable, source vetting matters, and you assume risk that emerging trial data may surface contraindications not yet known. Tirzepatide remains a more conservative choice until Retatrutide is approved.
Are there side effects beyond GLP-1 standard ones?
Yes — the glucagon arm adds: transient resting heart rate elevation (5-10 bpm during titration), mild transient liver enzyme elevation (typically resolves), and amplified GI burden vs Tirzepatide. Standard GLP-1 effects (nausea, constipation, fatigue) are also more pronounced during titration.
Related compounds
Often researched, stacked, or compared with Retatrutide.
Build your Retatrutide protocol with Coach
Coach personalizes the dose, stack, and cycle for your specific goals — and saves the result as a cited PDF you can bring to your doctor. Free for 14 days.
Start 14-Day Free TrialNo credit card · cancel anytime